For instance, in breast cancer, flavonoid drugs like apigenin have been confirmed to inhibit NF‐κB‐dependent production of CXCL10 in tumor cells, thereby reducing proliferation of precancerous epithelial cells and invasiveness of human breast cancer cells [513]. Here, CXCL10 is linked to breast carcinoma.